Compound having the structure of Formula I for use in treating neutrophil infiltration, hemorrhagic shock or lung inflammation in an individual: or a pharmaceutically acceptable salt thereof, wherein: L 1 is selected from the group consisting of C 3-6 alkyl, C 3-6 alkenyl, C 2-5 alkoxy, C 1-5 heteroalkyl, -CH 2 -C( R 10 )=N-, C 5-6 cycloalkyl, C 5-6 cycloalkenyl, and arylalkyl, each optionally substituted with one or more R 1A ; wherein where the arylalkyl substituent requires two points of attachment to the rest of the molecule, the arylalkyl is attached to the parent molecule through a carbon linkage in the aryl group and a carbon linkage in the alkyl group; R 10 is hydrogen or R 1A ; L 2 is aryl or heteroaryl each optionally substituted with one or more with one or more R 2A ; each R 1A isaryloptionally substituted with one or more R 1AA ; each R 1AA is independently selected from the group consisting of haloand (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro; each R 2A is independently selected from the group consisting of hydroxy, halo, nitro, and (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro; R 1 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of hydrogen, hydroxy, halo, nitro, -S(O) z N R 1B R 1C ,-C(=O) R 1D , (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, and (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro; each N R 1B R 1C is independently selected, wherein R 1B and R 1C are each independently from the group consisting of hydrogen and C 1-6 alkyl; each R 1D is independently selected from the group consisting of hydroxyl, heterocyclyl and (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, and (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro; X is O (oxygen), S (sulfur), N (nitrogen) or N R 11 ; each z is independently 0, 1 or 2; R 11 is H (hydrogen) or C 1-6 alkyl; X 2 is C (carbon), C R 12 , or N (nitrogen); R 12 is H (hydrogen) or C 1-6 alkyl; and each dashed line is an optional double bond. L 1 is selected from the group consisting of C 3-6 alkyl, C 3-6 alkenyl, C 2-5 alkoxy, C 1-5 heteroalkyl, -CH 2 -C( R 10 )=N-, C 5-6 cycloalkyl, C 5-6 cycloalkenyl, and arylalkyl, each optionally substituted with one or more R 1A ; wherein where the arylalkyl substituent requires two points of attachment to the rest of the molecule, the arylalkyl is attached to the parent molecule through a carbon linkage in the aryl group and a carbon linkage in the alkyl group; R 10 is hydrogen or R 1A ; L 2 is aryl or heteroaryl each optionally substituted with one or more with one or more R 2A ; each R 1A isaryloptionally substituted with one or more R 1AA ; each R 1AA is independently selected from the group consisting of haloand (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro; each R 2A is independently selected from the group consisting of hydroxy, halo, nitro, and (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro; R 1 , R 2 , R 3 , and R 4 are each independently selected from the group consisting of hydrogen, hydroxy, halo, nitro, -S(O) z N R 1B R 1C ,-C(=O) R 1D , (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, and (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro; each N R 1B R 1C is independently selected, wherein R 1B and R 1C are each independently from the group consisting of hydrogen and C 1-6 alkyl; each R 1D is independently selected from the group consisting of hydroxyl, heterocyclyl and (C 1 -C 6 )alkyl optionally substituted with up to 5 fluoro, and (C 1 -C 6 )alkoxy optionally substituted with up to 5 fluoro; X is O (oxygen), S (sulfur), N (nitrogen) or N R 11 ; each z is independently 0, 1 or 2; R 11 is H (hydrogen) or C 1-6 alkyl; X 2 is C (carbon), C R 12 , or N (nitrogen); R 12 is H (hydrogen) or C 1-6 alkyl; and each dashed line is an optional double bond. <EOS>